Future Outlook: A New Era of Weight Loss The emergence of drugs like Mounjaro and retatrutide signals a new era in obesity treatment
While thirst itself is not documented as a primary adverse effect in clinical trials, the medication can indirectly lead to increased thirst through several mechanisms, particularly gastrointestinal side effects that may cause dehydration
The orforglipron story reminds us that behind every breakthrough medication lies not just laboratory experimentation but sophisticated computational approaches that predict, optimize, and validate therapeutic potential
In 2025, only about 19% of companies with 200 or more workers and 43% of firms with 5,000 or more employees covered GLP-1s for weight loss in their largest health plan
Michael Anson*, Zhihong Guo*, Rafael de Cabo, Titilola Iyun, Michelle Rios, Adrienne Hagepanos, Donald K
Google Scholar 8 Bhattacharjee R, Thukral A, Chakraborty PP, Roy A, Goswami S, Ghosh S, et al
